# Sunitinib in Treating Patients With Recurrent Malignant Gliomas

> **NCT00499473** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Adult Anaplastic Astrocytoma
- Adult Diffuse Astrocytoma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Mixed Glioma
- Adult Oligodendroglioma
- Adult Pineal Gland Astrocytoma

## Interventions

- **DRUG:** sunitinib malate
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00499473
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-06
- **Final completion:** 2014-10
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2016-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499473, "Sunitinib in Treating Patients With Recurrent Malignant Gliomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00499473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*